Common secondary causes of resistant hypertension and rational for treatment

International Journal of Hypertension

Volumn 2011, Issue , 2011, Pages

  Faselis, Charles ^a   Doumas, Michael ^a   Papademetriou, Vasilios ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; DARUSENTAN; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETORICOXIB; HYDROCODONE; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; NAPROXCINOD; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PIROXICAM; PLACEBO; ROFECOXIB; SORAFENIB; SPIRONOLACTONE; SULINDAC; SUNITINIB; VASCULOTROPIN INHIBITOR;

ALCOHOL CONSUMPTION; ARTHRITIS; CAROTID SINUS PRESSORECEPTOR; CAUSAL ATTRIBUTION; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; KIDNEY DENERVATION; LIFESTYLE; MYALGIA; OBESITY; OSTEOARTHRITIS; PANCREAS CANCER; PATIENT COMPLIANCE; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROGNOSIS; RENOVASCULAR HYPERTENSION; RESISTANT HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SALT INTAKE; SEDENTARY LIFESTYLE; SENSORY STIMULATION; SLEEP DISORDERED BREATHING;

EID: 80054761122     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.4061/2011/236239     Document Type: Review

References (215)

1. Kearney P. M., Whelton M., Reynolds K., Muntner P., Whelton P. K., He J., Global burden of hypertension: analysis of worldwide data. Lancet 2005 365 9455 217 223 2-s2.0-12344282783 10.1016/S0140-6736(05)17741-1 (Pubitemid 40138015)
2. Calhoun D. A., Jones D., Textor S., Goff D. C., Murphy T. P., Toto R. D., White A., Cushman W. C., White W., Sica D., Ferdinand K., Giles T. D., Falkner B., Carey R. M., Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008 117 25 e510 e526 2-s2.0-49249106417 10.1161/HYPERTENSIONAHA.108.189141
3. Garg J. P., Elliott W. J., Folker A., Izhar M., Black H. R., Resistant hypertension revisited: a comparison of two university-based cohorts. American Journal of Hypertension 2005 18 5 619 626 2-s2.0-18844389740 10.1016/j.amjhyper.2004.11.021 (Pubitemid 40692429)
4. Papadopoulos D. P., Papademetriou V., Resistant hypertension: diagnosis and management. Journal of Cardiovascular Pharmacology and Therapeutics 2006 11 2 113 118 2-s2.0-33749033117 10.1177/1074248406289735 (Pubitemid 44449100)
5. Sarafidis P. A., Bakris G. L., Resistant hypertension. An overview of evaluation and treatment. Journal of the American College of Cardiology 2008 52 22 1749 1757 2-s2.0-56149084750 10.1016/j.jacc.2008.08.036
6. Alderman M. H., Resistant hypertension: a clinical syndrome in search of a definition. American Journal of Hypertension 2008 21 9 965 966 2-s2.0-50249161533 10.1038/ajh.2008.250
7. Moser M., Cushman W., Handler J., Resistant or difficult-to-treat hypertension. Journal of Clinical Hypertension 2006 8 6 434 440 2-s2.0-34249905554 10.1111/j.1524-6175.2006.05328.x
8. Amar J., Patients with resistant hypertension. Journal of Hypertensionn 2007 25 S3 S6 2-s2.0-34848884476
9. Epstein M., Resistant hypertension: prevalence and evolving concepts. Journal of Clinical Hypertension 2007 9 1 2 6 2-s2.0-34047267839
10. Pisoni R., Ahmed M. I., Calhoun D. A., Characterization and treatment of resistant hypertension. Current Cardiology Reports 2009 11 6 407 413 2-s2.0-72849129695 10.1007/s11886-009-0059-z
11. Woolf A. D., Pfleger B., Burden of major musculoskeletal conditions. Bulletin of the World Health Organization 2003 81 9 646 656 2-s2.0-0141920503 (Pubitemid 37254686)
12. Lohmander L. S., de Verdier M. G., Rollof J., Nilsson P. M., Engström G., Incidence of severe knee and hip osteoarthritis in relation to different measures of body mass: a population-based prospective cohort study. Annals of the Rheumatic Diseases 2009 68 4 490 496 2-s2.0-65249176782 10.1136/ard.2008.089748
13. Weber M. A., Treatment of patients with hypertension and arthritis pain: new concepts. American Journal of Medicine 2009 122 5 S16 S22 2-s2.0-64849109591 10.1016/j.amjmed.2009.03.004
14. Curhan G. C., Willett W. C., Rosner B., Stampfer M. J., Frequency of analgesic use and risk of hypertension in younger women. Archives of Internal Medicine 2002 162 19 2204 2208 2-s2.0-0037190699 10.1001/archinte.162.19.2204 (Pubitemid 35231589)
15. Dedier J., Stampfer M. J., Hankinson S. E., Willett W. C., Speizer F. E., Curhan G. C., Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002 40 5 604 608 2-s2.0-0036840954 10.1161/01.HYP. 0000035856.77718.DA (Pubitemid 35278593)
16. Zhang W., Moskowitz R. W., Nuki G., Abramson S., Altman R. D., Arden N., Bierma-Zeinstra S., Brandt K. D., Croft P., Doherty M., Dougados M., Hochberg M., Hunter D. J., Kwoh K., Lohmander L. S., Tugwell P., OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008 16 2 137 162 2-s2.0-38949130488 10.1016/j.joca.2007.12.013 (Pubitemid 351222155)
17. Zhang W., Doherty M., Leeb B. F., Alekseeva L., Arden N. K., Bijlsma J. W., Dinçer F., Dziedzic K., Häuselmann H. J., Herrero-Beaumont G., Kaklamanis P., Lohmander S., Maheu E., Martín-Mola E., Pavelka K., Punzi L., Reiter S., Sautner J., Smolen J., Verbruggen G., Zimmermann-Górska I., EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases 2007 66 3 377 388 2-s2.0-34147201733 10.1136/ard.2006.062091 (Pubitemid 46579641)
18. Forman J. P., Rimm E. B., Curhan G. C., Frequency of analgesic use and risk of hypertension among men. Archives of Internal Medicine 2007 167 4 394 399 2-s2.0-33847422246 10.1001/archinte.167.4.394 (Pubitemid 46333941)
19. Forman J. P., Stampfer M. J., Curhan G. C., Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005 46 3 500 507 2-s2.0-25444455368 10.1161/01.HYP.0000177437.07240.70 (Pubitemid 41376829)
20. Gurwitz J. H., Avorn J., Bohn R. L., Glynn R. J., Monane M., Mogun H., Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. Journal of the American Medical Association 1994 272 10 781 786 2-s2.0-0027936602 10.1001/jama.272.10.781 (Pubitemid 24275690)
21. Pope J. E., Anderson J. J., Felson D. T., A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Archives of Internal Medicine 1993 153 4 477 484 2-s2.0-0027472279 10.1001/archinte.153.4.477 (Pubitemid 23064991)
22. Johnson A. G., Nguyen T. V., Day R. O., Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Annals of Internal Medicine 1994 121 4 289 300 2-s2.0-0028580588
23. Chrischilles E. A., Wallace R. B., Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population. Journals of Gerontology 1993 48 3 M91 M96 2-s2.0-0027251342 (Pubitemid 23143642)
24. Johnson A. G., Simons L. A., Simons J., Friedlander Y., McCallum J., Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. British Journal of Clinical Pharmacology 1993 35 5 455 459 2-s2.0-0027215356 (Pubitemid 23158057)
25. Radack K. L., Deck C. C., Bloomfield S. S., Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Annals of Internal Medicine 1987 107 5 628 635 2-s2.0-0023621187 (Pubitemid 18041856)
26. Chalmers J. P., West M. J., Wing L. M. H., Bune A. J., Graham J. R., Effects of indomethacin, sulindac, naproxen, aspirin and paracetamol in treated hypertensive patients. Clinical and Experimental Hypertension A 1984 6 6 1077 1093 2-s2.0-0021241671 (Pubitemid 14083631)
27. Nawarskas J. J., Townsend R. R., Cirigliano M. D., Spinler S. A., Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. American Journal of Hypertension 1999 12 8 784 789 2-s2.0-0032835496 10.1016/S0895-7061(99)00037-0 (Pubitemid 29416793)
28. Avanzini F., avanzini@irfmn.mnegri.it Palumbo G., Alli C., Roncaglioni M. C., Ronchi E., Cristofari M., Capra A., Rossi S., Nosotti L., Costantini C., Pietrofeso R., Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. American Journal of Hypertension 2000 13 6, supplement 611 616 (Pubitemid 30461781)
29. Kurth T., Hennekens C. H., Sturmer T., Sesso H. D., Glynn R. J., Buring J. E., Gaziano J. M., Analgesic use and risk of subsequent hypertension in apparently healthy men. Archives of Internal Medicine 2005 165 16 1903 1909 2-s2.0-25144519089 10.1001/archinte.165.16.1903 (Pubitemid 41352086)
30. Aw T. J., Haas S. J., Liew D., Krum H., Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Archives of Internal Medicine 2005 165 5 490 496 2-s2.0-14844337012 10.1001/archinte.165.5.IOI50013 (Pubitemid 40344379)
31. Wolfe F., Zhao S., Reynolds M., Pettitt D., Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. Journal of Rheumatology 2004 31 6 1143 1151 2-s2.0-2642529302 (Pubitemid 38715891)
32. MacDonald T. M., Reginster J. Y., Littlejohn T. W., Richard D., Lheritier K., Krammer G., Rebuli R., Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. Journal of Hypertension 2008 26 8 1695 1702 2-s2.0-51549094845 10.1097/HJH.0b013e328302c9fe
33. Cannon C. P., Curtis S. P., FitzGerald G. A., Krum H., Kaur A., Bolognese J. A., Reicin A. S., Bombardier C., Weinblatt M. E., van der Heijde D., Erdmann E., Laine L., Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006 368 9549 1771 1781 2-s2.0-33750944984 10.1016/S0140-6736(06)69666-9 (Pubitemid 44739003)
34. Morgan T. O., Anderson A., Bertram D., Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. American Journal of Hypertension 2000 13 11 1161 1167 2-s2.0-0033763236 10.1016/S0895-7061(00)01204-8
35. White W. B., Kent J., Taylor A., Verburg K. M., Lefkowith J. B., Whelton A., Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002 39 4 929 934 2-s2.0-0036237083 10.1161/01.HYP.0000014323.99765.16 (Pubitemid 34437552)
36. Whelton A., White W. B., Bello A. E., Puma J. A., Fort J. G., Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. American Journal of Cardiology 2002 90 9 959 963 2-s2.0-0036830135 10.1016/S0002-9149(02)02661-9 (Pubitemid 35232619)
37. Cinotti G. A., Pugliese F., Prostaglandins in blood pressure regulation. Kidney International 1988 34 25 S57 S60 2-s2.0-0024084853
38. FitzGerald G. A., COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nature Reviews Drug Discovery 2003 2 11 879 890 2-s2.0-0242690224
39. Whelton A., Schulman G., Wallemark C., Drower E. J., Isakson P. C., Verburg K. M., Geis G. S., Effects of celecoxib and naproxen on renal function in the elderly. Archives of Internal Medicine 2000 160 10 1465 1470 2-s2.0-0034701938 (Pubitemid 30327449)
40. Catella-Lawson F., Mcadam B., Morrison B. W., Kapoor S., Kujubu D., Antes L., Lasseter K. C., Quan H., Gertz B. J., Fitzgerald G. A., Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. Journal of Pharmacology and Experimental Therapeutics 1999 289 2 735 741 2-s2.0-0032948948 (Pubitemid 29191226)
41. Patrono C., Dunn M. J., The clinical significance of inhibition of renal prostaglandin synthesis. Kidney International 1987 32 1 1 12 2-s2.0-0023178776 (Pubitemid 17094491)
42. Rossat J., Maillard M., Nussberger J., Brunner H. R., Burnier M., Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clinical Pharmacology and Therapeutics 1999 66 1 76 84 2-s2.0-0032777567 10.1016/S0009-9236(99)70056-1 (Pubitemid 29350448)
43. Johnson A. G., Nguyen T. V., Owe-Young R., Williamson D. J., Day R. O., Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. Journal of Human Hypertension 1996 10 4 257 261 2-s2.0-0029975222 (Pubitemid 26164369)
44. Lohmander L. S., McKeith D., Svensson O., Malmenäs M., Bolin L., Kalla A., Genti G., Szechinski J., Ramos-Remus C., A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Annals of the Rheumatic Diseases 2005 64 3 449 456 2-s2.0-14144252695 10.1136/ard.2004.023572 (Pubitemid 40283058)
45. Schnitzer T. J., Kivitz A. J., Lipetz R. S., Sanders N., Hee A., Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis & Rheumatism 2005 53 6 827 837 2-s2.0-29144446030 10.1002/art.21586 (Pubitemid 41811122)
46. Naproxcinod Baerwald C., Verdecchia P., Duquesroix B., Frayssinet H., Ferreira T., Efficacy, safety and effects on BP of Naproxcinod 750 Mg bid compared with Placebo and Naproxen 500 Mg bid in patients with osteoarthritis of the hip. Arthritis & Rheumatism 2010 62 12 3635 3644
47. Schnitzer T. J., Hochberg M. C., Marrero C. E., Duquesroix B., Frayssinet H., Beekman M., Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study. Seminars in Arthritis and Rheumatism 2011 40 4 285 297
48. Prentice R. L., On the ability of blood pressure effects to explain the relation between oral contraceptives and cardiovascular disease. American Journal of Epidemiology 1988 127 2 213 219 2-s2.0-0023832298 (Pubitemid 18056375)
49. Rosenthal T., Oparil S., Lip G., Hall J., Oral contraceptives, hormones replacement therapy, and hypertension. Comprehensive Hypertension 2007 New York, NY, USA Elsevier/Mosby
50. Chasan-Taber L., Willett W. C., Manson J. E., Spiegelman D., Hunter D. J., Curhan G., Colditz G. A., Stampfer M. J., Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996 94 3 483 489 2-s2.0-0029831866 (Pubitemid 26266136)
51. Lubianca J. N., Faccin C. S., Fuchs F. D., Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception 2003 67 1 19 24 2-s2.0-12244274969 10.1016/S0010-7824(02)00429-8 (Pubitemid 36084283)
52. White W. B., Hanes V., Chauhan V., Pitt B., Effects of a new hormone therapy, drospirenone and 17- β -estradiol, in postmenopausal women with hypertension. Hypertension 2006 48 2 246 253 2-s2.0-33748176511 10.1161/01.HYP.0000232179.60442.84 (Pubitemid 44309819)
53. World Health Organization, Low dose combined oral contraceptives. Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use 2004 3rd Geneva, Switzerland WHO
54. American College of Obstetricians and Gynecologists Practice Bulletin, Use of hormonal contraception in women with coexisting medical conditions: clinical management guidelines for obstetrician-gynecologists. Obstetrics & Gynecology 2006 107 1453 1472
55. Ferrara N., Hillan K. J., Gerber H. P., Novotny W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery 2004 3 5 391 400 2-s2.0-2442621619 (Pubitemid 38618122)
56. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004 350 23 2335 2342 2-s2.0-2542561964 10.1056/NEJMoa032691 (Pubitemid 38702844)
57. Shinkaruk S., Bayle M., Lain G., Deleris G., Vascular Endothelial Cell Growth Factor (VEGF), an emerging target for cancer chemotherapy. Current Medicinal ChemistryAnti-Cancer Agents 2003 3 2 95 117 2-s2.0-0037277722 10.2174/1568011033353452 (Pubitemid 36221732)
58. Sica D. A., Angiogenesis inhibitors and hypertension: an emerging issue. Journal of Clinical Oncology 2006 24 9 1329 1331 2-s2.0-33645451829 10.1200/JCO.2005.04.5740 (Pubitemid 46621994)
59. Verheul H. M. W., Pinedo H. M., Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Reviews Cancer 2007 7 6 475 485 2-s2.0-34249294557 10.1038/nrc2152 (Pubitemid 46809172)
60. Zhu X., Wu S., Dahut W. L., Parikh C. R., Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. American Journal of Kidney Diseases 2007 49 2 186 193 2-s2.0-33846638744 10.1053/j.ajkd.2006.11.039 (Pubitemid 46178407)
61. Wu S., Chen J. J., Kudelka A., Lu J., Zhu X., Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncology 2008 9 2 117 123 2-s2.0-38549085315 10.1016/S1470-2045(08)70003-2
62. Zhu X., Stergiopoulos K., Wu S., Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncologica 2009 48 1 9 17 2-s2.0-58149098429 10.1080/02841860802314720
63. Spano J. P., Chodkiewicz C., Maurel J., Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008 371 9630 2101 2108 2-s2.0-45449090215 10.1016/S0140-6736(08)60661-3
64. Friberg G., Kasza K., Vokes E. E., Kindler H. L., Early hypertension as a potential pharmacodynamic marker for survival in pancreatic cancer patients treated with bevacizumab and gemcitabine. Journal of Clinical Oncology 2005 23 16S, part I, article 3020
65. Schneider B. P., Wang M., Radovich M., Sledge G. W., Badve S., Thor A., Flockhart D. A., Hancock B., Davidson N., Gralow J., Dickler M., Perez E. A., Cobleigh M., Shenkier T., Edgerton S., Miller K. D., Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. Journal of Clinical Oncology 2008 26 28 4672 4678 2-s2.0-53749093040 10.1200/JCO.2008.16. 1612
66. Hood J. D., Meininger C. J., Ziche M., Granger H. J., VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. American Journal of PhysiologyHeart and Circulatory Physiology 1998 274 3 H1054 H1058 2-s2.0-0031943236
67. Gelinas D. S., Bernatchez P. N., Rollin S., Bazan N. G., Sirois M. G., Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. British Journal of Pharmacology 2002 137 7 1021 1030 2-s2.0-0036899189 10.1038/sj.bjp.0704956 (Pubitemid 35440742)
68. Horowitz J. R., Rivard A., van der Zee R., Hariawala M., Sheriff D. D., Esakof D. D., Muqtada Chaudhry G., Symes J. F., Isner J. M., Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension: evidence for a maintenance role in quiescent adult endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology 1997 17 11 2793 2800 2-s2.0-0031471950 (Pubitemid 28016023)
69. Ku D. D., Zaleski J. K., Liu S., Brock T. A., Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. American Journal of PhysiologyHeart and Circulatory Physiology 1993 265 2 H586 H592 2-s2.0-0027217832 (Pubitemid 23273595)
70. He H., Venema V. J., Gu X., Venema R. C., Marrero M. B., Caldwell R. B., Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src. Journal of Biological Chemistry 1999 274 35 25130 25135 2-s2.0-0033609922 10.1074/jbc.274.35.25130 (Pubitemid 29404726)
71. Wheeler-Jones C., Abu-Ghazaleh R., Cospedal R., Houliston R. A., Martin J., Zachary I., Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Letters 1997 420 1 28 32 2-s2.0-0031583917 10.1016/S0014-5793(97)01481-6 (Pubitemid 28037194)
72. Chen I. I. H., Prewitt R. L., Dowell R. F., Microvascular rarefaction in spontaneously hypertensive rat cremaster muscle. American Journal of PhysiologyHeart and Circulatory Physiology 1981 10 3 H306 H310 2-s2.0-0019452437
73. Hansen-Smith F. M., Morris L. W., Greene A. S., Lombard J. H., Rapid microvessel rarefaction with elevated salt intake and reduced renal mass hypertension in rats. Circulation Research 1996 79 2 324 330 2-s2.0-0030036854 (Pubitemid 26255886)
74. Hutchins P. M., Lynch C. D., Cooney P. T., Curseen K. A., The microcirculation in experimental hypertension and aging. Cardiovascular Research 1996 32 4 772 780 2-s2.0-0030270013 10.1016/0008-6363(96)00136-8 (Pubitemid 26332316)
75. Mourad J. J., des Guetz G., Debbabi H., Levy B. I., Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Annals of Oncology 2008 19 5 927 934 2-s2.0-43049085201 10.1093/annonc/mdm550 (Pubitemid 351627309)
76. Steeghs N., Gelderblom H., Roodt J. O., Christensen O., Rajagopalan P., Hovens M., Putter H., Rabelink T. J., De Koning E., Hypertension and rarefaction during treatment with telatinib, a Small molecule angiogenesis inhibitor. Clinical Cancer Research 2008 14 11 3470 3476 2-s2.0-50349101200 10.1158/1078-0432.CCR-07-5050
77. Veronese M. L., Mosenkis A., Flaherty K. T., Gallagher M., Stevenson J. P., Townsend R. R., O'Dwyer P. J., Mechanisms of hypertension associated with BAY 43-9006. Journal of Clinical Oncology 2006 24 9 1363 1369 2-s2.0-33645449812 10.1200/JCO.2005.02.0503 (Pubitemid 46621999)
78. Bottiglieri S., Muluneh B., Sutphin S., Blood pressure control in patients receiving bevacizumab in an outpatient cancer center. Journal of Oncology Pharmacy Practice. In press 10.1177/1078155210382150
79. Mir O., olivier.mir@cch.aphp.fr Coriat R., Ropert S., Cabanes L., Blanchet B., Camps S., Billemont B., Knebelmann B., Goldwasser F., Treatment of bevacizumab-induced hypertension by amlodipine. Investigational New Drugs. In press 10.1007/s10637-010-9549-5
80. Hita K. M., Young T. B., Bidwell T., Palta M., Skatrud J. B., Dempsey J., Sleep apnea and hypertension: a population-based study. Annals of Internal Medicine 1994 120 5 382 388 2-s2.0-23444451111 (Pubitemid 24066635)
81. Kraiczi H., Peker Y., Caidahl K., Samuelsson A., Hedner J., Blood pressure, cardiac structure and severity of obstructive sleep apnea in a sleep clinic population. Journal of Hypertension 2001 19 11 2071 2078 2-s2.0-0034755883 10.1097/00004872-200111000-00019 (Pubitemid 33035813)
82. Peppard P. E., Young T., Palta M., Skatrud J., Prospective study of the association between sleep-disordered breathing and hypertension. New England Journal of Medicine 2000 342 19 1378 1384 2-s2.0-0034636477 10.1056/ NEJM200005113421901 (Pubitemid 30262394)
83. Javier Nieto F., Young T. B., Lind B. K., Shahar E., Samet J. M., Redline S., D'Agostino R. B., Newman A. B., Lebowitz M. D., Pickering T. G., Association of sleep-disordered breathing sleep apnea, and hypertension in a large community-based study. Journal of the American Medical Association 2000 283 14 1829 1836 (Pubitemid 30207619)
84. Isaksson H., Svanborg E., Obstructive sleep apnea syndrome in male hypertensives, refractory to drug therapy. Nocturnal automatic blood pressure measurementsan aid to diagnosis? Clinical and Experimental Hypertension A 1991 13 6-7 1195 1212 2-s2.0-0026001469
85. Logan A. G., Perlikowski S. M., Mente A., Tisler A., Tkacova R., Niroumand M., Leung R. S. T., Bradley T. D., High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. Journal of Hypertension 2001 19 12 2271 2277 2-s2.0-0035215206 10.1097/00004872-200112000-00022 (Pubitemid 33135251)
86. Pratt-Ubunama M. N., Nishizaka M. K., Boedefeld R. L., Cofield S. S., Harding S. M., Calhoun D. A., Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007 131 2 453 459 2-s2.0-33847193562 10.1378/chest.06-1442
87. Lloberes P., plloberes@vhebron.net Lozano L., Sampol G., Romero O., Jurado M. J., Ríos J., Untoria M. D., Tovar J. L., Obstructive sleep apnoea and 24-h blood pressure in patients with resistant hypertension. Journal of Sleep Research 2010 19 4 597 602 10.1111/j.1365-2869.2010.00839.x
88. Goncalves S. C., Martinez D., Gus M., De Abreu-Silva E. O., Bertoluci C., Dutra I., Branchi T., Moreira L. B., Fuchs S. C., De Oliveira A. C. T., Fuchs F. D., Obstructive sleep apnea and resistant hypertension: a case-control study. Chest 2007 132 6 1858 1862 2-s2.0-37549018512 10.1378/chest.07-1170
89. Doherty L. S., Kiely J. L., Swan V., McNicholas W. T., Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 2005 127 6 2076 2084 2-s2.0-21844465408 10.1378/chest.127.6.2076
90. Marin J. M., Carrizo S. J., Vicente E., Agusti A. G. N., Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005 365 9464 1046 1053 2-s2.0-15244344823 10.1016/S0140-6736(05) 71141-7 (Pubitemid 40386782)
91. Ali N. J., Davies R. J. O., Fleetham J. A., Stradling J. R., The acute effects of continuous positive airway pressure and oxygen administration on blood pressure during obstructive sleep apnea. Chest 1992 101 6 1526 1532 2-s2.0-0026703760
92. Dimsdale J. E., Loredo J. S., Profant J., Effect of continuous positive airway pressure on blood pressure: a placebo trial. Hypertension 2000 35 1 144 147 2-s2.0-0033978496 (Pubitemid 30054251)
93. Faccenda J. F., Mackay T. W., Boon N. A., Douglas N. J., Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. American Journal of Respiratory and Critical Care Medicine 2001 163 2 344 348 2-s2.0-0035132074 (Pubitemid 32158510)
94. Barbé F., Mayoralas L. R., Duran J., Masa J. F., Maimó A., Montserrat J. M., Monasterio C., Bosch M., Ladaria A., Rubio M., Rubio R., Medinas M., Hernandez L., Vidal S., Douglas N. J., Agusti A. G. N., Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness: a randomized, controlled trial. Annals of Internal Medicine 2001 134 11 1015 1023 2-s2.0-0035811234 (Pubitemid 32488655)
95. Pepperell J. C. T., Ramdassingh-Dow S., Crosthwaite N., Mullins R., Jenkinson C., Stradling J. R., Davies R. J. O., Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002 359 9302 204 210 2-s2.0-0037132846 10.1016/S0140-6736(02)07445-7 (Pubitemid 34113817)
96. Barnes M., Houston D., Worsnop C. J., Neill A. M., Mykytyn I. J., Amanda K. A. Y., Trinder J., Saunders N. A., Douglas Mcevoy R., Pierce R. J., A randomized controlled trial of continuous positive airway pressure in mild obstructive sleep apnea. American Journal of Respiratory and Critical Care Medicine 2002 165 6 773 780 2-s2.0-0037086028 (Pubitemid 34229646)
97. Becker H. F., Jerrentrup A., Ploch T., Grote L., Penzel T., Sullivan C. E., Peter J. H., Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003 107 1 68 73 2-s2.0-0037422591 10.1161/01.CIR.0000042706.47107.7A (Pubitemid 36070935)
98. Norman D., Loredo J. S., Nelesen R. A., Ancoli-Israel S., Mills P. J., Ziegler M. G., Dimsdale J. E., Effects of continuous positive airway pressure versus supplemental oxygen on 24-hour ambulatory blood pressure. Hypertension 2006 47 5 840 845 2-s2.0-33646164661 10.1161/01.HYP.0000217128.41284.78 (Pubitemid 44297553)
99. Robinson G. V., Smith D. M., Langford B. A., Davies R. J. O., Stradling J. R., Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. European Respiratory Journal 2006 27 6 1229 1235 2-s2.0-33750623152 10.1183/09031936.06.00062805 (Pubitemid 44914309)
100. Campos-Rodriguez F., fcamposr@telefonica.net Grilo-Reina A., Perez-Ronchel J., Merino-Sanchez M., Gonzalez-Benitez M. A., Beltran-Robles M., Almeida-Gonzalez C., Effect of continuous positive airway pressure on ambulatory BP in patients with sleep apnea and hypertension: a placebo-controlled trial. Chest 2006 129 6 1459 1467 10.1378/chest.129.6.1459 (Pubitemid 43894973)
101. Hui D. S., To K. W., Ko F. W., Fok J. P., Chan M. C., Ngai J. C., Tung A. H., Ho C. W., Tong M. W., Szeto C. C., Yu C. M., Nasal CPAP reduces systemic blood pressure in patients with obstructive sleep apnoea and mild sleepiness. Thorax 2006 61 12 1083 1090 2-s2.0-33845200079 10.1136/thx.2006.064063 (Pubitemid 44852028)
102. Coughlin S. R., Mawdsley L., Mugarza J. A., Wilding J. P. H., Calverley P. M. A., Cardiovascular and metabolic effects of CPAP in obese males with OSA. European Respiratory Journal 2007 29 4 720 727 2-s2.0-34147099100 10.1183/09031936.00043306 (Pubitemid 46554622)
103. Kohler M., Pepperell J. C. T., Casadei B., Craig S., Crosthwaite N., Stradling J. R., Davies R. J. O., CPAP and measures of cardiovascular risk in males with OSAS. European Respiratory Journal 2008 32 6 1488 1496 2-s2.0-58849088445 10.1183/09031936.00026608
104. Campos-Rodriguez F., Perez-Ronchel J., Grilo-Reina A., Lima-Alvarez J., Benitez M. A., Almeida-Gonzalez C., Long-term effect of continuous positive airway pressure on BP in patients with hypertension and sleep apnea. Chest 2007 132 6 1847 1852 2-s2.0-37549061417 10.1378/chest.07-1478
105. Barbe F., Duran-Cantolla J., Capote F., Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. American Journal of Respiratory and Critical Care Medicine 2010 181 7 718 726 2-s2.0-77951901743 10.1164/rccm.200901-0050OC
106. Jaimchariyatam N., drboy48@yahoo.com Rodriguez C. L., RODRIGC2@ccf.org Budur K., ksbudur@yahoo.com Does CPAP treatment in mild obstructive sleep apnea affect blood pressure? Sleep Medicine 2010 11 9 837 842 10.1016/j.sleep.2010.05. 005
107. Bazzano L. A., Khan Z., Reynolds K., He J., Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 2007 50 2 417 423 2-s2.0-34547647774 10.1161/ HYPERTENSIONAHA.106.085175 (Pubitemid 47205794)
108. Haentjens P., patrick.haentjens@uzbrussel.be van Meerhaeghe A., Moscariello A., De Weerdt S., Poppe K., Dupont A., Velkeniers B., The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Archives of Internal Medicine 2007 167 8 757 765 10.1001/archinte.167.8.757 (Pubitemid 46658332)
109. Alajmi M., Mulgrew A. T., Fox J., Davidson W., Schulzer M., Mak E., Ryan C. F., Fleetham J., Choi P., Ayas N. T., Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials. Lung 2007 185 2 67 72 2-s2.0-34147108002 10.1007/s00408-006-0117-x (Pubitemid 46571874)
110. Pépin J.-L., JPepin@chu-grenoble.fr Tamisier R., Barone-Rochette G., Launois S. H., Lévy P., Baguet J.-P., Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. American Journal of Respiratory and Critical Care Medicine 2010 182 7 954 960 10.1164/rccm.200912-1803OC
111. Robinson G. V., Stradling J. R., Davies R. J. O., Sleep·6: obstructive sleep apnoea/hypopnoea syndrome and hypertension. Thorax 2004 59 12 1089 1094 2-s2.0-9644300995 10.1136/thx.2003.015875 (Pubitemid 39573930)
112. Logan A. G., Tkacova R., Perlikowski S. M., Leung R. S., Tisler A., Floras J. S., Bradley T. D., Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. European Respiratory Journal 2003 21 2 241 247 2-s2.0-12244252795 10.1183/09031936.03.00035402 (Pubitemid 36204537)
113. Martínez-García M. A., Gómez-Aldaraví R., Soler-Cataluña J. J., Martínez T. G., Bernácer-Alpera B., Román-Sánchez P., Positive effect of CPAP treatment on the control of difficult-to-treat hypertension. European Respiratory Journal 2007 29 5 951 957 2-s2.0-34248174802 10.1183/09031936.00048606 (Pubitemid 46711900)
114. Dernaika T. A., Kinasewitz G. T., Tawk M. M., Effects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apnea. Journal of Clinical Sleep Medicine 2009 5 2 103 107 2-s2.0-65349120772
115. Lozano L., Tovar J. L., Sampol G., Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. Journal of Hypertension 2010 28 2161 2168 2-s2.0-77953845206 10.1097/HJH.0b013e32833b9c63
116. Stepnowsky C. J. Jr., Moore P. J., Nasal CPAP treatment for obstructive sleep apnea: developing a new perspective on dosing strategies and compliance. Journal of Psychosomatic Research 2003 54 6 599 605 2-s2.0-0141783918 10.1016/S0022-3999(03)00038-2 (Pubitemid 38367953)
117. Engleman H. M., Wild M. R., Improving CPAP use by patients with the sleep apnoea/hypopnoea syndrome (SAHS). Sleep Medicine Reviews 2003 7 1 81 99 2-s2.0-0037317742 10.1053/smrv.2001.0197 (Pubitemid 36188308)
118. Weaver T. E., Grunstein R. R., Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proceedings of the American Thoracic Society 2008 5 2 173 178 2-s2.0-39049152378 10.1513/pats.200708-119MG (Pubitemid 351237875)
119. Kraiczi H., Hedner J., Peker Y., Grote L., Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. American Journal of Respiratory and Critical Care Medicine 2000 161 5 1423 1428 2-s2.0-0034032809 (Pubitemid 30329007)
120. Gaddam K., Pimenta E., Thomas S. J., Cofield S. S., Oparil S., Harding S. M., Calhoun D. A., dcalhoun@uab.edu Spironolactone reduces severity of
121. Conn J. W., Presidential address. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome. Journal of Laboratory and Clinical Medicine 1955 45 1 3 17 2-s2.0-2342642610
122. Kaplan N. M., Is there an unrecognized epidemic of primary aldosteronism? Con. Hypertension 2007 50 3 454 458 2-s2.0-34548644501
123. Calhoun D. A., Kaplan N. M., Is there an unrecognized epidemic of primary aldosteronism? (Pro). Hypertension 2007 50 3 447 458 2-s2.0-34548158515 10.1161/HYPERTENSIONAHA.106.086116 (Pubitemid 47312226)
124. Kaplan N. M., Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Annals of Internal Medicine 1967 66 6 1079 1090 2-s2.0-0014094503
125. Sinclair A. M., Isles C. G., Brown I., Cameron H., Murray G. D., Robertson J. W., Seconary hypertension in a blood pressure clinic. Archives of Internal Medicine 1987 147 7 1289 1296 (Pubitemid 17102157)
126. Gifford R. W. Jr., Evaluation of the hypertensive patient with emphasis on detecting curable causes. Milbank Memorial Fund Quarterly 1969 47 170 186
127. Andersen G. S., Toftdahl D. B., Lund J. O., Strandgaard S., Nielsen P. E., The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 19771981. Journal of Human Hypertension 1988 2 3 187 189 2-s2.0-0023685502
128. Lim P. O., Rodgers P., Cardale K., Watson A. D., MacDonald T. M., Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999 353 9146, article 40 2-s2.0-0033513989
129. Mulatero P., Stowasser M., Loh K. C., Fardella C. E., Gordon R. D., Mosso L., Gomez-Sanchez C. E., Veglio F., Young W. F., Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. Journal of Clinical Endocrinology and Metabolism 2004 89 3 1045 1050 2-s2.0-1642390149 10.1210/jc.2003-031337 (Pubitemid 38368386)
130. Fardella C. E., Mosso L., Gomez-Sanchez C., Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. Journal of Clinical Endocrinology and Metabolism 2000 85 5 1863 1867 2-s2.0-17744390208 10.1210/jc.85.5.1863 (Pubitemid 32269290)
131. Stowasser M., m.stowasser@uq.edu.au Gordon R. D., Gunasekera T. G., Cowley D. C., Ward G., Archibald C., Smithers B. M., High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. Journal of Hypertension 2003 21 11 2149 2157 10.1097/00004872-200311000-00025 (Pubitemid 38296877)
132. Schwartz G. L., Turner S. T., Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clinical Chemistry 2005 51 2 386 394 2-s2.0-12944260571 10.1373/clinchem.2004.041780 (Pubitemid 40175809)
133. Rossi G. P., gianpaolo.rossi@unipd.it Bernini G., Caliumi C., Desideri G., Fabris B., Ferri C., Ganzaroli C., Giacchetti G., Letizia C., Maccario M., Mallamaci F., Mannelli M., Mattarello M.-J., Moretti A., Palumbo G., Parenti G., Porteri E., Semplicini A., Rizzoni D., Rossi E., Boscaro M., Pessina A. C., Mantero F., A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology 2006 48 11 2293 2300 10.1016/j.jacc.2006.07.059 (Pubitemid 44873058)
134. Mosso L., Carvajal C., Gonzalez A., Barraza A., Avila F., Montero J., Huete A., Gederlini A., Fardella C. E., Primary aldosteronism and hypertensive disease. Hypertension 2003 42 2 161 165 2-s2.0-0042266234 10.1161/01.HYP. 0000079505.25750.11 (Pubitemid 36944590)
135. Strauch B., Zelinka T., Hampf M., Bernhardt R., Widimsky J. Jr., Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. Journal of Human Hypertension 2003 17 5 349 352 2-s2.0-0037500115 10.1038/sj.jhh.1001554 (Pubitemid 36625965)
136. Stowasser M., Gordon R. D., Primary aldosteronismcareful investigation is essential and rewarding. Molecular and Cellular Endocrinology 2004 217 1-2 33 39 2-s2.0-2342513477 10.1016/j.mce.2003.10.006 (Pubitemid 38596626)
137. Mulatero P., Dluhy R. G., Giacchetti G., Boscaro M., Veglio F., Stewart P. M., Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends in Endocrinology and Metabolism 2005 16 3 114 119 2-s2.0-15944423279 10.1016/j.tem.2005.02.007 (Pubitemid 40432461)
138. Calhoun D. A., Nishizaka M. K., Zaman M. A., Thakkar R. B., Weissman P., High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002 40 892 896 (Pubitemid 35434912)
139. Gallay B. J., Ahmad S., Xu L., Toivola B., Davidson R. C., Screening for primary hyperaldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. American Journal of Kidney Diseases 2001 37 699 705 (Pubitemid 32268029)
140. Eide I. K., Torjesen P. A., Drolsum A., Babovic A., Lilledahl N. P., Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. Journal of Hypertension 2004 22 11 2217 2226 2-s2.0-7744227337 10.1097/00004872-200411000-00026 (Pubitemid 39463817)
141. Martell N., Rodriguez-Cerrillo M., Grobee D. E., High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension. Blood Press 2003 12 149 154 (Pubitemid 36874763)
142. Umpierrez G. E., Cantey P., Smiley D., Palacio A., Temponi D., Luster K., Chapman A., Primary Aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007 30 7 1699 1703 2-s2.0-34447136684 10.2337/dc07-0031 (Pubitemid 47036339)
143. Douma S., Petidis K., Doumas M., Papaefthimiou P., Triantafyllou A., Kartali N., Papadopoulos N., Vogiatzis K., Zamboulis C., Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008 371 9628 1921 1926 2-s2.0-44649150565 10.1016/S0140-6736(08) 60834-X (Pubitemid 351778191)
144. Gonzaga C. C., carolinadcg@hotmail.com Gaddam K. K., Ahmed M. I., Pimenta E., Thomas S. J., Harding S. M., Oparil S., Cofield S. S., Calhoun D. A., Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. Journal of Clinical Sleep Medicine 2010 6 4 363 368
145. Di Murro A., Petramala L., Cotesta D., Zinnamosca L., Crescenzi E., Marinelli C., Saponara M., Letizia C., claudio.letizia@uniroma1.it Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. Journal of the Renin-Angiotensin-Aldosterone System 2010 11 3 165 172 10.1177/1470320310366581
146. Sica D. A., Endocrine causes of secondary hypertension. Journal of Clinical Hypertension 2008 10 7 534 540 2-s2.0-54449097580 10.1111/j.1751-7176. 2008.08097.x
147. Mazza A., Armigliato M., Zamboni S., Rempelou P., Rubello D., Pessina A. C., Casiglia E., Endocrine arterial hypertension: therapeutic approach in clinical practice. Minerva Endocrinologica 2008 33 4 297 312 2-s2.0-60849123466
148. Coresh J., Wei G. L., McQuillan G., Brancati F. L., Levey A. S., Jones C., Klag M. J., Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third national health and nutrition examination survey (19881994). Archives of Internal Medicine 2001 161 9 1207 1216 2-s2.0-0034927743 (Pubitemid 32691517)
149. Mancia G., de Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., Grassi G., Heagerty A. M., Kjeldsen S. E., Laurent S., Narkiewicz K., Ruilope L., Rynkiewicz A., Schmieder R. E., Boudier H. A. J. S., Zanchetti A., 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2007 25 6 1105 1187 2-s2.0-34250350040 10.1097/HJH.0b013e3281fc975a (Pubitemid 46924065)
150. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jones D. W., Materson B. J., Oparil S., Wright J. T., Roccella E. J., Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003 42 6 1206 1252 2-s2.0-0347423198 10.1161/01.HYP.0000107251.49515.c2 (Pubitemid 37553153)
151. Levey A. S., Rocco M. V., Anderson S., Andreoli S. P., Bailie G. R., Bakris G. L., Callahan M. B., Greene J. H., Johnson C. A., Lash J. P., McCullough P. A., Miller E. R., Nally J. V., Pirsch J. D., Portman R. J., Sevick M. A., Sica D., Wesson D. E., Agodoa L., Bolton K., Cutler J. A., Hostetter T., Lau J., Uhlig K., Chew P., Kausz A., Kupelnick B., Raman G., Sarnak M., Wang C., Astor B. C., Eknoyan G., Levin A., Levin N., Bailie G., Becker B., Becker G., Burrowes J., Carrera F., Churchill D., Collins A., Crooks P. W., DeZeeuw D., Golper T., Gotch F., Gotto A., Greenwood R., Greer J. W., Grimm R., Haley W. E., Hogg R., Hull A. R., Hunsicker L., Klag M., Klahr S., Lameire N., Locatelli F., McCulloch S., Michael M., Newmann J. M., Nissenson A., Norris K., Obrador G., Owen W., Patel T. G., Payne G., Ronco C., Rivera-Mizzoni R. A., Schoolwerth A. C., Star R., Steffes M., Steinman T., Wauters J. P., Wenger N., Briggs J., Burrows-Hudson S., Latos D., Mapes D., Oberley E., Pereira B. J. G., Willis K., Gucciardo A., Fingerhut D., Klette M., Schachne E., K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. American Journal of Kidney Diseases 2004 43 5 1 290 2-s2.0-17044450690
152. Cushman W. C., William.Cushman@med.va.gov Ford C. E., Cutler J. A., Margolis K. L., Davis B. R., Grimm R. H., Black H. R., Hamilton B. P., Holland J., Nwachuku C., Papademetriou V., Probstfield J., Wright Jr. J. T., Alderman M. H., Weiss R. J., Piller L., Bettencourt J., Walsh S. M., Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attact trial (ALLHAT). Journal of Clinical Hypertension 2002 4 6 393 404 (Pubitemid 35469393)
153. Saelen M. G., Prosch L. K., Gudmundsdottir H., Dyrbekk D., Hunderi O. H., Arnesen E., Paulsen D., Skjonsberg H., Os I., Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function. Blood Pressure 2005 14 3 170 176 2-s2.0-22544460534 10.1080/08037050510008959 (Pubitemid 41015716)
154. Kaplan N. M., Norman.Kaplan@UTSouthwestern.edu Resistant hypertension. Journal of Hypertension 2005 23 8 1441 1444 (Pubitemid 41104810)
155. Campese V. M., Mitra N., Sandee D., Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney International 2006 69 6 967 973 2-s2.0-33644856338 10.1038/sj.ki.5000177 (Pubitemid 43372170)
156. Singer G. M., Izhar M., Black H. R., Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002 40 4 464 469 2-s2.0-0036790755 10.1161/01.HYP.0000035858.04434.03
157. Casas J. P., juan.pablo-casas@lshtm.ac.uk Chua W., Loukogeorgakis S., Vallance P., Smeeth L., Hingorani A. D., MacAllister R. J., Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005 366 9502 2026 2033 10.1016/S0140-6736(05)67814-2 (Pubitemid 41773378)
158. ONTARGET Investigators, Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine 2008 358 1547 1559
159. Mann J. F., Schmieder R. E., McQueen M., Dyal L., Schumacher H., Pogue J., Wang X., Maggioni A., Budaj A., Chaithiraphan S., Dickstein K., Keltai M., Metsärinne K., Oto A., Parkhomenko A., Piegas L. S., Svendsen T. L., Teo K. K., Yusuf S., Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008 372 9638 547 553 2-s2.0-49149087718 10.1016/S0140-6736(08)61236-2
160. Sarafidis P. A., Bakris G. L., Renin-angiotensin blockade and kidney disease. Lancet 2008 372 9638 511 512 2-s2.0-49149131161 10.1016/S0140-6736(08) 61212-X
161. Safian R. D., Textor S. C., Renal-artery stenosis. New England Journal of Medicine 2001 344 6 431 442 2-s2.0-0035825718 10.1056/NEJM200102083440607 (Pubitemid 32128677)
162. White C. J., Catheter-based therapy for atherosclerotic renal artery stenosis. Circulation 2006 113 11 1464 1473 2-s2.0-33645830487 10.1161/CIRCULATIONAHA.105.540039 (Pubitemid 43739443)
163. Aqel R. A., Zoghbi G. J., Baldwin S. A., Abo Auda W. S., Calhoun D. A., Coffey C. S., Perry G. J., Iskandrian A. E., Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. Journal of Hypertension 2003 21 6 1157 1162 2-s2.0-0037865202 10.1097/00004872-200306000- 00016 (Pubitemid 36667870)
164. Tumelero R. T., Duda N. T., Tognon A. P., Thiesen M., Prevalence of renal artery stenosis in 1,656 patients who have undergone cardiac catheterization. Arquivos Brasileiros de Cardiologia 2006 87 3 213 253 2-s2.0-33750348078
165. Anderson G. H. Jr., Blakeman N., Streeten D. H. P., The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. Journal of Hypertension 1994 12 5 609 615 2-s2.0-0028236204 10.1097/00004872-199405000-00015 (Pubitemid 24192887)
166. Crowley J. J., Santos R. M., Peter R. H., Puma J. A., Schwab S. J., Phillips H. R., Stack R. S., Conlon P. J., Progression of renal artery stenosis in patients undergoing cardiac catheterization. American Heart Journal 1998 136 5 913 918 2-s2.0-0031790901 10.1016/S0002-8703(98)70138-3 (Pubitemid 28506893)
167. Leiner T., de Haan M. W., Nelemans P. J., Engelshoven J. M., Vasbinder G. B. C., Contemporary imaging techniques for the diagnosis of renal artery stenosis. European Radiology 2005 15 11 2219 2229 2-s2.0-27744553413 10.1007/s00330-005-2826-6 (Pubitemid 41600106)
168. ASTRAL Investigators, Revascularization versus medical therapy for renal artery stenosis. New England Journal of Medicine 2009 361 1953 1962
169. Cooper C. J., Murphy T. P., Matsumoto A., Steffes M., Cohen D. J., Jaff M., Kuntz R., Jamerson K., Reid D., Rosenfield K., Rundback J., Agostino R. D., Henrich W., Dworkin L., Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. American Heart Journal 2006 152 1 59 66 2-s2.0-33745659870 10.1016/j.ahj.2005.09.011 (Pubitemid 43974724)
170. Caro J. J., Salas M., Speckman J. L., Raggio G., Jackson J. D., Persistence with treatment for hypertension in actual practice. Canadian Medical Association Journal 1999 160 1 31 37 2-s2.0-0033547740 (Pubitemid 29054224)
171. Mazzaglia G., Mantovani L. G., Sturkenboom M. C. J. M., Filippi A., Trifirò G., Cricelli C., Brignoli O., Caputi A. P., Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. Journal of Hypertension 2005 23 11 2093 2100 2-s2.0-29244462820 (Pubitemid 41830406)
172. van Wijk B. L. G., Klungel O. H., Heerdink E. R., de Boer A., Rate and determinants of 10-year persistence with antihypertensive drugs. Journal of Hypertension 2005 23 11 2101 2107 2-s2.0-28844436931 (Pubitemid 41830407)
173. Vrijens B., Vincze G., Kristanto P., Urquhart J., Burnier M., Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. British Medical Journal 2008 336 7653 1114 1117 2-s2.0-44349111871 10.1136/bmj.39553.670231.25 (Pubitemid 351731741)
174. Corrao G., Zambon A., Parodi A., Poluzzi E., Baldi I., Merlino L., Cesana G., Mancia G., Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. Journal of Hypertension 2008 26 4 819 824 2-s2.0-40449097623 10.1097/HJH.0b013e3282f4edd7 (Pubitemid 351354932)
175. Conlin P. R., Gerth W. C., Fox J., Roehm J. B., Boccuzzi S. J., Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clinical Therapeutics 2001 23 12 1999 2010 2-s2.0-0035695926 10.1016/S0149-2918(01)80152-1 (Pubitemid 34073191)
176. de Souza W. A., Sabha M., de Faveri Favero F., Bergsten-Mendes G., Yugar-Toledo J. C., Moreno H., Intensive monitoring of adherence to treatment helps to identify "true" resistant hypertension. Journal of Clinical Hypertension 2009 11 4 183 191 2-s2.0-65449136694 10.1111/j.1751-7176.2009. 00102.x
177. Park J., Campese V., Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. Journal of Clinical Hypertension 2007 9 1 7 12 2-s2.0-34047248060
178. Hyman D. J., Pavlik V. N., Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Archives of Internal Medicine 2000 160 15 2281 2286 2-s2.0-0034726375
179. Oliveria S. A., Lapuerta P., McCarthy B. D., L'Italien G. J., Berlowitz D. R., Asch S. M., Physician-related barriers to the effective management of uncontrolled hypertension. Archives of Internal Medicine 2002 162 4 413 420 2-s2.0-0037169922 (Pubitemid 34150642)
180. Trewet C. L., Ernst M. E., Resistant hypertension: identifying causes and optimizing treatment regimens. Southern Medical Journal 2008 101 2 166 173 2-s2.0-41249103273
181. Phillips L. S., Branch W. T., Cook C. B., Doyle J. P., El-Kebbi I. M., Gallina D. L., Miller C. D., Ziemer D. C., Barnes C. S., Clinical inertia. Annals of Internal Medicine 2001 135 9 825 834 2-s2.0-0035818550 (Pubitemid 33051266)
182. Furmaga E. M., Cunningham F. E., Cushman W. C., National utilization of antihypertensive medications from 20002006 in the Veterans Health Administration: focus on thiazides diuretics. Journal of Clinical Hypertension 2008 10 770 778
183. Egan B. M., Zhao Y., Axon R. N., US trends in prevalence, awareness, treatment, and control of hypertension, 19882008. Journal of the American Medical Association 2010 303 20 2043 2050 2-s2.0-77952750659 10.1001/jama.2010.650
184. Falaschetti E., Chaudhury M., Mindell J., Poulter N., Continued improvement in hypertension management in England: results from the health survey for England 2006. Hypertension 2009 53 3 480 486 2-s2.0-61749091927 10.1161/HYPERTENSIONAHA.108.125617
185. McInnis N. H., Fodor G., Moy Lum-Kwong M., Leenen F. H. H., Antihypertensive medication use and blood pressure control: a community-based cross-sectional survey (ON-BP). American Journal of Hypertension 2008 21 11 1210 1215 2-s2.0-54249119018 10.1038/ajh.2008.269
186. Pickering T. G., Hall J. E., Appel L. J., Falkner B. E., Graves J., Hill M. N., Jones D. W., Kurtz T., Sheps S. G., Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humansa statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on high blood pressure research. Circulation 2005 111 5 697 716 10.1161/01.CIR.0000154900.76284.F6 (Pubitemid 40216499)
187. Moser M., Setaro J. F., Resistant or difficult-to-control hypertension. New England Journal of Medicine 2006 355 4 385 392 10.1056/NEJMcp041698 (Pubitemid 44127541)
188. Calhoun D. A., Jones D., Textor S., Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008 117 e510 e526
189. Sarafidis P. A., Bakris G. L., State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. Journal of Clinical Hypertension 2008 10 2 130 139 2-s2.0-42049112222 10.1111/j.1751-7176.2008.07309.x
190. Redon J., Campos C., Narciso M. L., Rodicio J. L., Pascual J. M., Ruilope L. M., Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998 31 2 712 718 2-s2.0-0031933420
191. Pierdomenico S. D., Lapenna D., Bucci A., Di Tommaso R., Di Mascio R., Manente B. M., Caldarella M. P., Neri M., Cuccurullo F., Mezzetti A., Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. American Journal of Hypertension 2005 18 11 1422 1428 2-s2.0-27644538062 10.1016/j.amjhyper.2005.05. 014 (Pubitemid 41566669)
192. Brown M. A., Buddle M. L., Martin A., Is resistant hypertension really resistant? American Journal of Hypertension 2001 14 12 1263 1269 2-s2.0-0035216183 10.1016/S0895-7061(01)02193-8 (Pubitemid 33151484)
193. Nishizaka M. K., Zaman M. A., Calhoun D. A., Efficacy of low-dose spironolactone in subjects with resistant hypertension. American Journal of Hypertension 2003 16 11 925 930 2-s2.0-0142231538 10.1016/S0895-7061(03)01032-X (Pubitemid 37315491)
194. Pimenta E., Gaddam K. K., Oparil S., Aban I., Husain S., Dell'Italia L. J., Calhoun D. A., Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009 54 3 475 481 2-s2.0-70349249634 10.1161/HYPERTENSIONAHA.109. 131235
195. Ramsay L. E., Silas J. H., Freestone S., Diuretic treatment of resistant hypertension. British Medical Journal 1980 281 6248 1101 1103 (Pubitemid 10021412)
196. Ouzan J., Perault C., Lincoff A. M., Carré E., Mertes M., The role of spironolactone in the treatment of patients with refractory hypertension. American Journal of Hypertension 2002 15 4 333 339 2-s2.0-0036110762 10.1016/S0895-7061(01)02342-1 (Pubitemid 34408973)
197. Mahmud A., Mahgoub M., Hall M., Feely J., Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? American Journal of Hypertension 2005 18 12 1631 1635 2-s2.0-29144455401 10.1016/j.amjhyper.2005.06.010 (Pubitemid 41814688)
198. Saha C., Eckert G. J., Ambrosius W. T., Chun T. Y., Wagner M. A., Zhao Q., Pratt J. H., Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005 46 3 481 487 2-s2.0-25444446626 10.1161/01.HYP.0000179582.42830.1d (Pubitemid 41376826)
199. Sharabi Y., Adler E., Shamis A., Nussinovitch N., Markovitz A., Grossman E., Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. American Journal of Hypertension 2006 19 7 750 755 2-s2.0-33745273601 10.1016/j.amjhyper.2005.11.016 (Pubitemid 43928519)
200. de Souza F., Muxfeldt E., Fiszman R., Salles G., Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010 55 1 147 152 2-s2.0-73849140879 10.1161/HYPERTENSIONAHA.109. 140988
201. Hood S. J., Taylor K. P., Ashby M. J., Brown M. J., The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007 116 3 268 275 2-s2.0-34547559617 10.1161/CIRCULATIONAHA.107. 690396 (Pubitemid 47196562)
202. Lane D. A., Shah S., Beevers D. G., Low-dose spironolactone in the management of resistant hypertension: a surveillance study. Journal of Hypertension 2007 25 4 891 894 2-s2.0-33947162019 10.1097/HJH.0b013e328014954d (Pubitemid 46398886)
203. Chapman N., Dobson J., Wilson S., Dahlöf B., Sever P. S., Wedel H., Poulter N. R., Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007 49 4 839 845 2-s2.0-34047197931 10.1161/01.HYP.0000259805.18468.8c (Pubitemid 351664214)
204. Lane D. A., Beevers D. G., Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. Journal of Hypertension 2007 25 12 2515 2516 2-s2.0-35848965472 10.1097/HJH.0b013e3282f254d9 (Pubitemid 350060395)
205. Parthasarathy H. K., Alhashmi K., McMahon A. D., Struthers A. D., McInnes G. T., Ford I., Connell J. M., MacDonald T. M., Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. Journal of Hypertension 2010 28 1 170 177 2-s2.0-73849092227 10.1097/HJH.0b013e328332b79b
206. Hermida R. C., Ayala D. E., Fernandez J. R., Calvo C., Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 2008 51 1 69 76 2-s2.0-37349007842 10.1161/HYPERTENSIONAHA.107.096933 (Pubitemid 350307106)
207. Minutolo R., roberto.minutolo@unina2.it Gabbai F. B., Borrelli S., Scigliano R., Trucillo P., Baldanza D., Laurino S., Mascia S., Conte G., de Nicola L., Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. American Journal of Kidney Diseases 2007 50 6 908 917 10.1053/j.ajkd.2007.07.020 (Pubitemid 350122805)
208. Tsioufis C., Kasiakogias A., Thomopoulos C., Manolis A., Stefanadis C., Managing hypertension in obstructive sleep apnea: the interplay of continuous positive airway pressure, medication and chronotherapy. Journal of Hypertension 2010 28 5 875 882 2-s2.0-77951266289 10.1097/HJH.0b013e328336ed85
209. Weber M. A., michaelwebermd@cs.com Black H., Bakris G., Krum H., Linas S., Weiss R., Linseman J. V., Wiens B. L., Warren M. S., Lindholm L. H., A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009 374 9699 1423 1431 10.1016/S0140-6736(09) 61500-2
210. Bakris G. L., gbakris@gmail.com Lindholm L. H., Black H. R., Krum H., Linas S., Linseman J. V., Arterburn S., Sager P., Weber M., Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010 56 5 824 830 10.1161/HYPERTENSIONAHA.110. 156976
211. Oliver J. J., Dear J. W., Webb D. J., Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension 2010 56 1 62 67 2-s2.0-77953807828 10.1161/HYPERTENSIONAHA.109.147686
212. Doumas M., Guo D., Papademetriou V., Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. Expert Opinion on Therapeutic Targets 2009 13 4 413 425 2-s2.0-64049119196 10.1517/14728220902780185
213. Doumas M., Faselis C., Papademetriou V., Renal sympathetic denervation and systemic hypertension. American Journal of Cardiology 2010 105 4 570 576 2-s2.0-75349085866 10.1016/j.amjcard.2009.10.027
214. Scheffers I. J. M., Kroon A. A., Schmidli J., Jordan J., Tordoir J. J. M., Mohaupt M. G., Luft F. C., Haller H., Menne J., Engeli S., Ceral J., Eckert S., Erglis A., Narkiewicz K., Philipp T., de Leeuw P. W., p.deleeuw@intmed. unimaas.nl Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. Journal of the American College of Cardiology 2010 56 15 1254 1258 10.1016/j.jacc.2010.03.089
215. Krum H., Schlaich M., Whitbourn R., Sobotka P. A., Sadowski J., Bartus K., Kapelak B., Walton A., Sievert H., Thambar S., Abraham W. T., Esler M., Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009 373 9671 1275 1281 2-s2.0-64049084640 10.1016/S0140-6736(09)60566-3